Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload.
Source: FierceBiotech
You may also like
Cancer, immune drugmakers dominate VC funding so far...
Beyond Boston: Unlikely cities stake biotech claims
Vera Therapeutics wins FDA nod for closely watched...
Gene editing developer Scribe plots an IPO
Novartis to acquire ADC developer in a deal worth up...
Scribe notes down IPO ambition to fund lipid-lowering...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.